Els Hubloux
Partner @ Newton Biocapital
Brussels, Belgium
Els Hubloux is a seed investor at Newton Biocapital in Brussels focused on Biotechnology and Medical. Els Hubloux - Partner @ Newton Biocapital
- Total investments:
- 3
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Els Hubloux invests in
Stages Els Hubloux invests in
Countries Els Hubloux invests in
Investment Focus
Industry
- Biotechnology 2 (67%)
- Medical 1 (33%)
- Health Care 1 (33%)
- Manufacturing 1 (33%)
- Medical Device 1 (33%)
Stage
- Seed 1 (33%)
- Series A 1 (33%)
- Series B 1 (33%)
Country
- Belgium 1 (33%)
- Switzerland 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
DeuterOncology
|
DeuterOncology is a preclinical-stage biotech company focusing on the development of a first-in-class dual MET and RAS pathway inhibitor for targeted cancer therapies. | $6.1M / Series A / Jan 19, 2023 | |
|
DeuterOncology
|
DeuterOncology is a preclinical-stage biotech company focusing on the development of a first-in-class dual MET and RAS pathway inhibitor for targeted cancer therapies. | Seed / Feb 24, 2021 | |
Sequana Medical
|
Sequana Medical is a Swiss medical device company providing implantable pump systems to manage fluid balance within the body. This system is designed to move excess fluid to the bladder, where it is passed naturally from the body through normal urination.Sequana Medical’s first product, the Alfapump System, is an innovative solution for themanagement of ascites. Ascites is a fluid that collects in the abdominal cavity in people with advanced liver disease, certain cancers, or congestive heart failure. Alfapump System was the first and only system for the automatic and continual removal of ascites.Sequana Medical was founded in 2006 and is based in Zurich, Switzerland. | $27.6M / Series B / Mar 09, 2011 |
Co-Investors
About Newton Biocapital
Newton Biocapital is a Venture Capital Fund incorporated in Belgium, focused on financing biotech and life science projects in the "core of Europe" (B, NL, D, F) and Japan for the prevention and treatment of chronic diseases.Their approach as lead investor is to support promising start-up projects as well as neglected or undervaluedlate-stage projects, in order to mitigate the risks and to create investor value. The leadership team consi.sts of specialists with long-standing management and investor experience who coach bio-entrepreneurs through the development stages of their projects.
Newton Biocapital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Els Hubloux
Partner
|
|||
Goro Takeda
Managing Partner
|
|||
Toshiyuki Mori
Partner, Tokyo
|
|||
Alain Parthoens
Managing Partner and Founder
|
|||
1 more contact available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Els Hubloux invest in?
Els Hubloux invests primarily in Biotechnology, Medical and Health Care startups, most often at Seed and Series A stage. Most of the 3 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Els Hubloux last invest?
The most recent investment recorded for Els Hubloux closed in Jan 2023. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
